The Otsuka Long-Evans Tokushima Fatty (OLETF) rat is an established model of human type 2 diabetes mellitus. We investigated the effect of the oral administration of disulfiram (DSF), a powerful antioxidant, on some blood test values of diabetes mellitus in OLETF rats. DSF (100 or 200 mg/kg body weight/day) was administered orally to rats once a day (5:00 PM) beginning when the rats were 7 weeks of age, and the plasma levels of glucose (PG), triglycerides (TG), total cholesterol (Total-cho) and insulin were measured from 10 to 38 weeks of age. The PG, TG, Total-cho and insulin levels did not change with aging in Long-Evans Tokushima Otsuka (LETO) rats, the strain used as a normal control. In contrast to the results in LETO rats, PG, TG and Total-cho levels all increased in OLETF rats with aging. The plasma insulin level in OLETF rats was also significantly higher than in LETO rats from 20 to 38 week of age. The Total-cho level in OLETF rats did not differ significantly between the saline and DSF administered groups. On the other hand, the oral administration of DSF attenuated the age-related increase in PG and TG levels in OLETF rats. In addition, the insulin level in DSF-administered OLETF rats was higher in comparison with saline-administered rats. The present study demonstrates that the oral administration of DSF to OLETF rats potently prevents the increase in PG levels and the decrease in insulin levels suggesting that DSF may provide effective therapy for type 2 diabetes mellitus.
INTRODUCTION
Diabetes mellitus is a common metabolic disorder, affecting more than 190 million people worldwide 1, 2) . The prevalence of type 2 diabetes mellitus is increasing rapidly and is affecting the health of millions of humans, and will continue to do so in the near future. Among the factors responsible for the increasing prevalence of this disease are obesity, the consumption of energy-dense diets and low levels of physical activity 3) . The development of type 2 diabetes mellitus is associated with pancreatic b-cell dysfunction occurring together with insulin resistance. Normal bcells can compensate for insulin resistance by increasing insulin secretion, but insufficient compensation leads to the onset of glucose intolerance. Once hyperglycemia becomes apparent, b-cell function progressively deteriorates: glucose-induced insulin secretion becomes further impaired and degranulation of b-cells becomes evident, often accompanied by a decrease in the number of b-cells [4] [5] [6] [7] . Recently, it was reported that the production of reactive oxygen species (ROS) mediated by glycation reduces insulin gene transcription and decreases the number of bcells through apoptosis 8, 9) . Once b-cells are exposed to ROS under diabetic conditions they are likely to be profoundly damaged due to their low levels of antioxidant enzyme expression 10) . Therefore, the development of safe and powerful antioxidant drugs is highly expected as therapy for type 2 diabetes mellitus.
The association between alcohol and type 2 diabetes mellitus has been investigated in several studies but with contradictory results 11) . However, it is known that excessive alcohol consumption can exert a diabetogenic influence by increasing adiposity 12, 13) , a condition that is known to result in insulin resistance. Disulfiram (DSF), a dimer of diethyldithiocarbamate, has long been used to treat alco-holic syndrome without severe side effects 14) . In addition, DSF is a powerful antioxidant that scavenges reactive oxygen species such as hydroxyl radical, superoxide, peroxynitrite in rats 15, 16) . Therefore, we investigated the administration of DSF as a therapy for type 2 diabetes mellitus.
In studies of therapeutic agents against diabetes mellitus, the selection of the experimental animal is very important. The Otsuka Long-Evans Tokushima Fatty (OLETF) rat is an established model of human type 2 diabetes mellitus 17) . Nearly 100% of male OLETF rats develop a diabetic syndrome by 25 weeks of age, and hyperglycemia and hyperinsulinemia are exhibited in the early phase of the disease as a result of islet cell hyperplasia and peripheral insulin resistance [18] [19] [20] . With increasing age, the rats eventually develop hypoinsulinemia as a result of the deterioration of the b-cell islets by ROS 20) . These changes in the biological characteristics of OLETF rats correspond to those of human type 2 diabetes mellitus. Therefore, OLETF rats may provide a useful model for studies to develop drugs for type 2 diabetes mellitus therapy. In this study, we examined the effects of the oral administration of DSF, a powerful antioxidant, on some blood test values for diabetes mellitus (e.g. glucose, triglycerides, cholesterol and insulin) in OLETF rats. We also investigated the preventive effects of the oral administration of DSF on hyperglycemia and the deterioration of the b-cell islets in OLETF rats with hyperglycemia (30-week-old OLETF rat) and deterioration of the b-cell islets (38-week-old OLETF rat).
EXPERIMENTAL

1
Male Long-Evans Tokushima Otsuka (LETO) rats as normal controls and OLETF rats aged 7 to 38 weeks were used in this study. The LETO and OLETF rats were obtained from the Otsuka Pharmaceutical Co., Ltd. and housed under standard conditions (12 h/d fluorescent light (07:00-19:00), 25 room temperature) with free access to a commercial diet (CE-2, Clea Japan Inc., Tokyo, Japan) and water. The drug used was disulfiram (DSF, Ouchi Shinko Chemical, Tokyo, Japan). DSF was suspended in saline solution containing 0.5% methylcellulose. Low-DSF (100 mg/kg body weight/day) or high-DSF (200 mg/kg body weight/day) doses were administered orally to the rats once a day (5:00 PM) beginning when the rats were 7 weeks of age. In the experiments, the rats were divided into four groups (i.e. LETO rat administered with saline containing 0.5% methylcellulose (normal), OLETF rats administered with saline containing 0.5% methylcellulose (control), OLETF rats administered with Low-DSF (Low-DSF), OLETF rats administered with High-DSF (High-DSF)), and were housed separately. All procedures were performed in accordance with the guidelines of the Kinki University School of Pharmacy Committee for the Care and Use of Laboratory Animals.
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Body weights, g -glutamyl transpeptidase (g -GTP) levels and some blood test parameters for diabetes mellitus were measured from 10 to 38 weeks of age. Blood was drawn from a tail vein of each rat fasted for 15 h at AM 9:00 without anesthesia, and plasma glucose (PG), triglycerides (TG), total cholesterol (Total-cho), insulin and g -GTP levels were measured. The PG and TG levels were determined by the Accutrend GCT (Roche Diagnostics, Mannheim, Germany). The Total-cho levels were measured by the cholesterol oxidase method and Phosphotungstate-magnesium salt method using a Cholesterol E-Test Kit (Wako, Osaka, Japan). Insulin levels were measured using an ELISA Insulin Kit according to the manufacturer's instructions (Morinaga Institute of Biological Science Inc., Kanagawa, Japan). Briefly, monoclonal antibodies specific for rat insulin were pre-coated onto microplates, standards and samples were pipetted into the wells, and the microplates were incubated at 4 for 2 h. After washing to remove unbound materials, rat insulin antibodies were added to the wells at room temperature for 30 min. After washing, the substrates were added. The enzyme reactions yielded blue products that turned yellow when the stop solutions were added. The absorbance was measured with a microplate reader (BIO-RAD, California, USA) at 450 nm. g-GTP levels were measured by g -GTP C-Test Kit (Wako, Osaka, Japan).
The exacerbation of some blood test indicators for diabetes mellitus (PG, TG, Total-cho) are represented as AUC (the area under the blood test value-time curve). The AUC 10-38w (AUC during 10-38 weeks) was calculated from the following equation : (1) where V and t are the blood test values for diabetes mellitus (e. g. PG, TG, Total-cho) and the age in weeks, respectively.
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All values are represented as mean standard error of the mean (S.E.). Statistical differenceswere evaluated by one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison. P values less than 0.05 were considered significant. shows the changes in body weight and food intake of LETO and OLETF rats administered with saline or DSF for 10-38 weeks of age. The body weights of 10week-old OLETF rats were already higher than those of 10-week-old LETO rats by approximately 1.35-fold. The food intakes of OLETF rats were higher than those of LETO rats. However, there were no significant differences observed in the body weights or food intakes of the OLETF rats between the saline and DSF administered groups.
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shows changes in PG, TG, Total-cho and insulin and g -GTP levels of LETO and OLETF rats administered with saline or DSF. The AUC 10-38w values for three parameters (i.e. PG, TG, Total-cho) for 10-38 week-old OLETF rats are also shown in to clarify the therapeutic effect of DSF on diabetes mellitus. PG, TG, Total-cho and insulin levels did not change with age in LETO rats. In contrast, PG, TG, Total-cho levels increased with age in OLETF rats. Plasma insulin levels in OLETF rats were also higher than in LETO rats. The oral administration of high dose DSF significantly attenuated the rises in PG and TG levels in OLETF rats (
). In addition, the insulin level in the OLETF rats receiving the high dose DSF was significantly higher at 38 weeks of age than in the saline-administered OLETF rats. On the other hand, no significant change was observed in the Total-cho level between saline and high dose DSF administered OLETF rats. The plasma g -GTP levels did not change with age in OLETF rats, and DSF administration had no effect on these levels.
DISCUSSION
diabetes mellitus results from the failure of pancreatic b-cells to adequately compensate for obesity and insulin resistance 21) . Recently, it was reported that ROS production mediated by glycation reduces insulin gene transcription and decreases the number of b-cells through apoptosis 8, 9) . In this study, we investigated the effect of the oral administration of DSF, a powerful antioxidant, on high blood glucose levels in OLETF rats, a model of human 2 type diabetes mellitus. We also investigated the preventive effects of the oral administration of DSF on hyperglycemia and the deterioration of the b-cell islets in OLETF rats with hyperglycemia (30-week-old OLETF rat) and deterioration of the b-cell islets (38-week-old OLETF rat).
The OLETF rat is an established model of human type 2 diabetes mellitus 17) . It has been reported that an increase in TG causes islet cell hyperplasia and peripheral insulin resistance, resulting in hyperglycemia and hyperinsulinemia [18] [19] [20] . In this study, the body weights of OLETF rats were approximately 1.35-fold those of LETO rats ( ). PG, TG and Total-cho levels in OLETF rats increased with age, and their levels were all significantly higher than in LETO rats. On the other hand, plasma insulin levels in OLETF rats were consistently higher than in LETO rats.
These results indicate that the 20-38-week-old OLETF rats used in this study developed diabetes mellitus via insulin resistance. The oral administration of high dose DSF significantly attenuated the increase in PG levels in OLETF rats; however, the food intakes of OLETF rats administered with DSF did significantly not differ from those administered with saline. These results suggested that the oral administration of DSF increase glucose tolerance in OLETF rat. In addition, the DSF administration may be safe treatment for human type 2 diabetes mellitus, since the oral administration of high dose DSF did not affect the g -GTP levels, which indicate a hepatic function.
It is very important to elucidate the mechanism of the preventive effect of DSF against the increases in PG levels. When there are long-term high blood glucose concentrations, the production of various reducing sugars increases as a result of enhancements in glycolysis and the polyol pathway, which leads to an increase in ROS production through the induction of the glycation reaction 22, 23) . b-Cells, in which the formation of advanced glycation end products can be detected when there are high blood glucose concentrations 22) , cannot be excluded from this phenomenon. Enhanced ROS production induces apoptosis 9) , an increase in cyclin-dependent kinase inhibitor p21 23) and a decrease in the expression of pancreatic and duodenal homeobox factor-1 8) in pancreatic b-cells, resulting in a decrease in the number of b-cells and glucose-stimulated insulin secretion 8, 24) . Hirashima et al. reported the b-cells in OLETF rats also atrophy or disappear with aging, and that the plasma insulin level in OLETF rats over 60 weeks of age is lower than in same age LETO rats 25, 26) . In this study, the insulin levels of 30-week-old OLETF rat was increased by its insulin resistance, and the insulin levels of 38-week-old OLETF rat was significantly lower than that of the 30week-old OLETF rat. Therefore, it was suggested that the decrease of insulin levels was caused by apoptosis of bcells. On the other hand, we show that the plasma insulin levels of OLETF rats administered with high dose DSF (200 mg/kg/day), a powerful antioxidant 14) , are consistently higher than in OLETF rats administered with saline, and that the plasma insulin levels in 20, 30 and 38-weeks-old OLETF rats administered with high dose DSF were found to be approximately 1.53, 1.55 and 1.88-fold those of same aged OLETF rats administered with saline. In addition, the enhancement of TG levels, which caused insulin resistance in OLETF rat, was significantly attenuated by the oral administration of DSF in comparison with saline-adminis-tered OLETF rat. When the results are taken together, the plasma high insulin levels in OLETF rats administered with DSF may be caused by protection against the decrease in the number of b-cells and glucose-stimulated insulin secretion via its powerful antioxidative reaction, resulting in the decrease in PG levels in OLETF rats administered with DSF.
On the other hand, it is also important to clarify the decrease in plasma TG levels in DSF-administered OLETF rats. Sadur and Eckel 27) have reported that insulin increases lipoprotein lipase activity, which decomposes plasma TG to glycerol and free fatty acids in adipose tissue. Therefore, the enhancement in the blood insulin level in DSF-administered OLETF rats may also lead to moderately decreased plasma TG levels. mechanisms by which DSF administration leads to a suppression of blood glucose and TG levels. In addition, it is important to clarify the relationship among blood insulin levels, insulin resistance and DSF dose. Therefore, we will next investigate the effect of DSF on the number of b-cells and glucose-stimulated insulin secretion in OLETF rats.
CONCLUSION
The present study demonstrates the oral administration of DSF to OLETF rats has a potent preventive effect on the increase in PG levels and decrease in insulin levels that occur in this strain with age. Our findings suggest that DSF may provide an effective therapy for a type 2 diabetes mellitus, and can be used to design further studies aimed at developing drugs to treat type 2 diabetes mellitus. 
